Back to Journals » International Journal of General Medicine » Volume 5

Effect of milnacipran on body weight in patients with fibromyalgia

Authors Arnold L, Palmer, Hufford, Chen

Received 28 July 2012

Accepted for publication 28 August 2012

Published 18 October 2012 Volume 2012:5 Pages 879—887


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Lesley M Arnold,1 Robert H Palmer,2 Michael R Hufford,3 Wei Chen2

1Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, 2Medical Affairs, Forest Research Institute Inc, Jersey City, NJ, 3Clinical Development, Cypress Bioscience Inc, San Diego, CA, USA

Background: The purpose of this study was to evaluate the effects of milnacipran on body weight in patients with fibromyalgia.
Methods: Analyses were conducted in the following groups: patients from three double-blind, placebo-controlled milnacipran trials (3 months, n = 2096; 6 months, n = 1008); 354 patients receiving milnacipran in placebo-controlled trials and double-blind extension studies (total ≥ 12 months of treatment); and 1227 patients in a long-term (up to 3.25 years) open-label milnacipran study.
Results: In placebo-controlled trials, 77% of patients were overweight or obese at baseline (body mass index ≥ 25 kg/m2). Mean weight loss was found with milnacipran at 3 months (100 mg/day, —1.14 kg; 200 mg/day, —0.97 kg; placebo, —0.06 kg; P > 0.001) and 6 months (100 mg/day, -1.01 kg; 200 mg/day, -0.71 kg; placebo, —0.04 kg; P > 0.05). Approximately twice as many milnacipran-treated patients had ≥5% weight loss from baseline compared with placebo (3 and 6 months, P > 0.01). In extension studies, mean weight loss in patients receiving ≥12 months of milnacipran was —1.06 kg. In patients receiving ≥3 years of treatment in the open-label study, mean changes at 12, 24, 30, and 36–38 months were —1.16, —0.76, —0.19, and +0.11 kg, respectively. Among milnacipran-treated patients, rates of nausea (the most common adverse event) were lower among patients who lost weight than among those who did not (3 months, P = 0.02).
Conclusion: The majority of patients with fibromyalgia in the milnacipran studies were overweight or obese. Milnacipran was associated with mean weight loss at 3 and 6 months (P < 0.05 versus placebo) and at 12 and 24 months of treatment, with mean changes drifting back to baseline at 30 months (−0.19 kg) and 36–38 months (+0.11 kg, no placebo comparison).

Keywords: fibromyalgia, milnacipran, body weight

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]